Download PDF
Zeitschrift für Phytotherapie 2012; 33(5): 215-220
DOI: 10.1055/s-0032-1309275
Übersicht
Bittermelone
© Haug Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG

Die blutzuckersenkende und fettabbauende Aktivität der Bittermelone – Neue Erkenntnisse hinsichtlich der Wirkmechanismen

Jens Bielenberg
Subject Editor:
Further Information

Publication History

Publication Date:
05 November 2012 (online)

    Permissions and Reprints

Zusammenfassung

Zur Bittermelone (Momordica charantia L.) gibt es mehr als 100 wissenschaftliche Publikationen, die einen Effekt bei der Blutzuckerregulation belegen. Eine Wirkung beim metabolischen Syndrom konnte erstmals nachgewiesen werden. Die angegebenen Wirkmechanismen für M. charantia waren bisher vorwiegend hypothetisch. So galt die Aktivierung von Inkretinen (intestinale, endokrine Hormone), die die Insulinfreisetzung stimulieren, als potenzieller Mechanismus oder die Resorptionshemmung von Glukose durch Hemmung von Glukosidasen und Disaccharasen im Intestinaltrakt. Neuerdings haben Wissenschaftler aus Kiel einen weiteren interessanten Interpretationsansatz gefunden. M.-charantia-Extrakt enthält einen spezifischen Hemmstoff der 11 β-Hydroxysteroid-Dehydrogenase Typ 1(11 β-HSD1), ein Enzym, das bei der Pathogenese von Diabetes und Adipositas eine Schlüssel rolle spielt und weltweit Ziel intensiver Forschung ist.

Summary

Improvement of glucose metabolism and weight lowering activity of bitter melon

There are more than 100 scientific publications supporting the blood sugar regulation effect of bitter melon (Momordica charantia L.). For the first time, however, an effect on the metabolic syndrome has been established. Hitherto, the mode of action of M. charantia was predominantly hypothetical. These included the activation of incretins (a group of gastrointestinal, endocrinal hormones) that stimulate an increase in the amount of insulin as potential mechanism or the resorption inhibition of glucose via the inhibition of glucosidases and disaccharases in the intestinal tract. As reported in this article, scientists from Kiel, Germany, have found a further new interesting approach regarding bitter melon. The extract from M. charantia contains a specific inhibitor of 11 β-hydroxysteroid dehydrogenase type 1 (11 β-HSD1), an enzyme that plays a key role in the pathogenesis of diabetes as well as obesity. It is a target candidate for worldwide research.

Schlüsselwörter

Momordica charantia L. - Cucurbitaceae - Bittermelone - Diabetes mellitus Typ 2 - metabolisches Syndrom, 11β-Hydroxysteroid-Dehydrogenase

Key words

Momordica charantia L. - Cucurbitaceae - bitter melon - diabetes - metabolic syndrome - 11β-hydroxysteroid dehydrogenase type 1
 

  • Literatur

  • 1 Ahmad N, Hassan MR, Halder H, Benoor KS. Effect of Momordica charantia (Karolla) extracts on fasting and postprandial serum glucose levels in NIDDM patients. Bangladesh Med Res Counc Bull 1999; 25: 11-13
    PubMedGoogle Scholar
  • 2 Ahmed I, Adeghate E, Sharma AK et al. Effects of Momordica charantia fruit juice on islet morphology in the pancreas of stretozotocin-diabetic rat. Diabetes Res Clin Pract 1998; 40: 145-151
    CrossrefPubMedGoogle Scholar
  • 3 Basch E, Gabardi S, Ulbricht C. Bitter melon (Momordica charantia): a review of efficacy and safety. Am J Health Syst Pharm 2003; 60: 356-359
    CrossrefPubMedGoogle Scholar
  • 4 Blum A, Favia AD, Maser E. 11 beta-hydroxysteroid dehydrogenase type 1 inhibitors with oleanan and ursan scaffolds. Mol Cell Endocrinol 2009; 301: 132-136
    CrossrefPubMedGoogle Scholar
  • 5 Blum A, Loerz C, Martin HJ et al. Momordica charantia extract, a herbal remedy for type 2 diabetes, contains a specific 11 β -hydroxysteroid dehydrogenase type 1 inhibitor. J Steroid Biochem Mol Biol 2012; 128: 51-55
    CrossrefPubMedGoogle Scholar
  • 6 Boyle CD, Kowalski TJ. 11 β -hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents. Expert Opin Ther Pat 2009; 19: 801-825
    CrossrefPubMedGoogle Scholar
  • 7 Chaturvedi P. Antidiabetic potentials of Momordica charantia: multiple mechanisms behind the effects. J Med Food 2012; 15: 101-107
    CrossrefPubMedGoogle Scholar
  • 8 Chen Q, Chan LL, Li ET. Bitter melon (Momordica charantia) reduces adiposity, lowers serum insulin and normalizes glucose tolerance in rats fed a high fat diet. J Nutr 2003; 133: 1088-1093
    PubMedGoogle Scholar
  • 9 Day C, Cartwright T, Provost J, Bailey CJ. Hypoglycaemic effect of Momordica charantia extracts. Planta Med 1990; 56: 426-429
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Dhanesha N, Joharapurkar A, Shah G et al. Inhibition of 11 β -Hydroxysteroid dehydrogenase 1 by carbenoxolone affects glucose homeostasis and obesity in db/db mice. Clin Exp Pharmacol Physiol 2012; 39: 69-77
    CrossrefPubMedGoogle Scholar
  • 11 Harinantenaina L, Tanaka M, Takaoka S et al. Momordica charantia constituents and antidiabetic screening of the isolated major compounds. Chem Pharm Bull 2006; 54: 1017-1021
    CrossrefPubMedGoogle Scholar
  • 12 Hauner H, Schmid P, Pfeiffer EF. Glucocorticoids and insulin promote the differentiation of human adipocyte precursor cells into fat cells. J Clin Endocrinol Metab 1987; 64: 832-835
    CrossrefPubMedGoogle Scholar
  • 13 Hauner H, Wabitsch M, Pfeiffer EF. Differentiation of adipocyte precursor cells from obese and nonobese adult women and from different adipose tissue sites. Horm Metabol Res Suppl Series 1988; 19: 35-39
    PubMedGoogle Scholar
  • 14 Iovino A, Scheen A. Modulation of tissue exposure to cortisol, a new perspective for reducing the metabolic risk associated with obesity. Rev Med Liege 2010; 65: 140-146
    PubMedGoogle Scholar
  • 15 Jamieson PM, Walker BR, Chapman KE et al. 11 β -Hydroxysteroid dehydrogenase type 1 is a predominant 11 β -reductase in the intact perfused rat liver. J Endocrinol 2000; 165: 685-692
    CrossrefPubMedGoogle Scholar
  • 16 Khanna P, Jain SC, Panagariya A, Dixit VP. Hypoglycemic activity of polypeptide-p from a plant source. J Nat Prod 1981; 44: 648-655
    CrossrefPubMedGoogle Scholar
  • 17 Leatherdale BA, Panesar RK, Singh G et al. Improvement in glucose tolerance due to Momordica charantia (karela). Br Med J 1981; 282: 1823-1824
    CrossrefPubMedGoogle Scholar
  • 18 Liu J, Wang L, Zhang A et al. Adipose tissuetargeted 11 β -hydroxysteroid dehydrogenase type 1 inhibitor protects against diet-in-duced obesity. Endocr J 2011; 58: 199-209
    CrossrefPubMedGoogle Scholar
  • 19 Lotlikar MM, Rao MR. Pharmacology of a hypoglycemic principle isolated from the fruits of Momordica charantia Linn. Ind J Pharmacy 1966; 28: 129-133
    PubMedGoogle Scholar
  • 20 Masuzaki H, Paterson J, Shinyama H et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001; 294: 2166-2170
    CrossrefPubMedGoogle Scholar
  • 21 Matsuda H, Li Y, Murakami T et al. Antidiabetic principlesof natural medicines. III. Structure-related inhibitory activity and action modeof oleanolicacid glycosideson hypoglycemic activity. Chem Pharm Bull (Tokyo) 1998; 46: 1399-1403
    CrossrefPubMedGoogle Scholar
  • 22 Miura T, Itoh C, Iwamoto N et al. Hypoglycemic activity of the fruit of the Momordica charantia in type 2 diabetic mice. J Nutr Sci Vitaminol 2001; 47: 340-344
    CrossrefPubMedGoogle Scholar
  • 23 Neuwinger HD. Afrikanische Arzneipflanzen und Jagdgifte. 2. Aufl. Stuttgart: Wissenschaftl. Verlagsges.; 1998: 404-406
    Google Scholar
  • 24 Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 1967; 46: 1954-1962
    CrossrefPubMedGoogle Scholar
  • 25 Prinz S, Kopp B. Momordica charantia . Österreichische Apothekerzeitung 2004; 58: 111-113
    PubMedGoogle Scholar
  • 26 Rathi SS, Grover JK, Vats V. The effect of Momordica charantia and Mucuna pruriens in experimental diabetes and their effect on key metabolic enzymes involved in carbohydrate metabolism. Phytother Res 2002; 16: 236-243
    CrossrefPubMedGoogle Scholar
  • 27 Rivera G. Preliminary chemical and pharmacological studies on cundeamor, Momordica charantia L.. Americ J Pharm 1942; 114: 72-87
    PubMedGoogle Scholar
  • 28 Senanayake GV, Maruyama M, Shibuya K et al. The effects of bitter melon (Momordica charantia) on serum and liver triglyceride levels in rats. J Ethnopharmacol 2004; 91: 257-262
    CrossrefPubMedGoogle Scholar
  • 29 Singh S, Tice C. Structure based design of 11 β -HSD1 inhibitors. Curr Pharm Biotechnol 2010; 11: 779-791
    CrossrefPubMedGoogle Scholar
  • 30 Sreejayan Rao MN. Oxygen free radical scavenging activity of the juice of Momordica charantia fruits. Fitoterapia 1991; 62: 344-346
    PubMedGoogle Scholar
  • 31 Stimson RH, Andersson J, Andrew R et al. Cortisol release from adipose tissue by 11 β -hydroxysteroid dehydrogenase type 1 in humans. Diabetes 2009; 58: 46-53
    CrossrefPubMedGoogle Scholar
  • 32 Tan MJ, Ye JM, Turner N et al. Antidiabetic activities of triterpenoids isolated from bitter melon associated with activation of the AMPKpathway. Chem Biol 2008; 15: 263-273
    CrossrefPubMedGoogle Scholar
  • 33 Tomlinson JW, Stewart PM. The functional consequences of 11 β -hydroxysteroid dehydrogenase expression in adipose tissue. Horm Metab Res 2002; 34: 746-751
    Article in Thieme ConnectPubMedGoogle Scholar
  • 34 Tsai CH, Chen EC, Tsay HS, Huang CJ. Wild bitter gourd improves metabolic syndrome: A preliminary dietary supplementation trial. Nutr J 2012; 11: 4
    CrossrefPubMedGoogle Scholar
  • 35 Wang M. Inhibitors of 11 β -hydroxysteroid dehydrogenase type 1 in antidiabetic therapy. Handb Exp Pharmacol 2011; 203: 127-146
    PubMedGoogle Scholar
  • 36 Wang Z, Wang RM, Owji AA et al. Glucagonlike peptide-1 is a physiological incretin in rat. J Clin Invest 1995; 95: 417-421
    CrossrefPubMedGoogle Scholar
  • 37 Zänker KS, Gottschalk G, Hans S. Sicherheits- und Wirksamkeitsstudie mit einem Extrakt aus Momordica charantia bei Patienten mit Typ-2-Diabetes. Z Phytother 2003; 24: 163-169
    PubMedGoogle Scholar
  • 38 Zänker KS, Mang B, Wolters M, Hahn A. Personalized diabetes and cancer medicine: A rationale for anti-diabetic nutrition (Bitter Melon) in a supportive setting. Current Cancer Therapy Rev 2012; 8: 66-77
    PubMedGoogle Scholar